| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.56 |
| 52 Week High | SEK 4.12 |
| 52 Week Low | SEK 2.45 |
| Beta | 1.62 |
| 11 Month Change | -13.59% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIMG.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -1.9% |
| 1Y | n/a | 25.8% | 30.4% |
Return vs Industry: Insufficient data to determine how VIMG.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how VIMG.F performed against the US Market.
Price Volatility
| VIMG.F volatility | |
|---|---|
| VIMG.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VIMG.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VIMG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMG.F fundamental statistics | |
|---|---|
| Market cap | US$2.18b |
| Earnings (TTM) | US$278.59k |
| Revenue (TTM) | US$383.49m |
7,708x
P/E Ratio5.6x
P/S RatioIs VIMG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMG.F income statement (TTM) | |
|---|---|
| Revenue | €352.39m |
| Cost of Revenue | €105.67m |
| Gross Profit | €246.72m |
| Other Expenses | €246.46m |
| Earnings | €256.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.00049 |
| Gross Margin | 70.01% |
| Net Profit Margin | 0.073% |
| Debt/Equity Ratio | 35.9% |
How did VIMG.F perform over the long term?
See historical performance and comparison